Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-15 (cancelled)

Claim 16 (withdrawn): A sorption complex comprising the compound of claim 1 directly linked to the constant region of a Fab fragment of a human IgG of κ-type, or a functional derivative thereof.

Claim 17 (currently amended): A separation matrix for affinity chromatography, comprising ligands coupled to a support, wherein the majority of the ligands are the compounds of formula (I)



(I)

wherein

R_1 is CH_3 or CH_2CH_3;

R_2 is a *para* and/or *meta* substituted phenyl group having substituents selected from the group consisting of F, Cl, Br, I, OH and a group $-O-R_5$, wherein R_5 is either CH_3 or CH_2CH_3;

R_3 is H, CH_3 or CH_2CH_3; and

R_4 is a linear or cyclic aliphatic group,

or, wherein

R_1 and R_2 are as stated above while R_3 and R_4 are parts of a 4- to 6-membered cyclic entity,

and which compound has affinity for human IgG of κ-type;

further wherein said ligands are coupled to said support through the group R_4.

Claim 18 (previously presented): The separation matrix of claim 17, wherein the ligands have been coupled to the support via linkers.

Claim 19 (previously presented): The separation matrix of claim 17, wherein the support is a porous polymeric particle.

Claim 20 (cancelled)

Claim 21 (withdrawn): A system suitable for affinity chromatography, comprising the separation matrix of claim 17 packed in a column.

Claim 22 (previously presented): The separation matrix of claim 17, wherein the compounds of formula (I) is an affinity ligand with affinity for the constant region of a Fab fragment of human IgG of κ-type.

Claim 23 (previously presented): The separation matrix of claim 17, wherein R_1 is CH_3.

Claims 24-25 (cancelled)

Claim 26 (currently amended): The separation matrix of claim 17 ~~claim 24~~, wherein the phenyl group of R_2 is substituted with Cl or F in the *meta* position.

Claim 27 (currently amended): The separation matrix of claim 17 ~~claim 24~~, wherein the phenyl group of R_2 is substituted with Cl in *meta* and *para* position.

Claim 28 (previously presented): The separation matrix of claim 17, wherein R_4 is an aliphatic group, which includes oxygen atoms in one or more positions.

Claim 29 (previously presented): The separation matrix of claim 17, wherein R_4 is an aliphatic group, which contains one or more carbonyl groups.

Claim 30 (previously presented): The separation matrix of claim 17, wherein R_4 is an aliphatic group which includes a terminating functionality selected from the group consisting of a carboxylic acid, nitrogen, oxygen, sulphur or any derivative thereof.

Claim 31 (previously presented): The separation matrix of claim 17, wherein R_1 is CH_3; R_2 is a phenyl group that has been substituted with Cl in *meta* and *para* position; and R_3 and R_4 are parts of a cyclic 5-membered group.

Claim 32 (previously presented): The separation matrix of claim 31, wherein the cyclic 5-membered entity is substituted in a position directly adjacent to N with a C(O)-O-CH3 group.

Claim 33 (previously presented): The separation matrix of claim 17, wherein said compounds of formula (I) are capable of binding to the constant region of a human IgG of κ-type, or a functional derivative thereof, with a binding constant of at least 10^{-3} M.

Claim 34 (previously presented): The separation matrix of claim 17, wherein said compounds of formula (I) are capable of binding to the constant region of a human IgG of κ-type, or a functional derivative thereof, via a binding pocket-defined by the structure coordinates of the amino acids as shown in Fig 6.